1 completed, 1 enrolling by invitation, 1 recruiting, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Fludarabine and Melphalan: new trials by email Literature Review of Fludarabine and Melphalan trials Research Report on Fludarabine and Melphalan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Fludarabine and Busulfan, Fludarabine and Melphalan - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS) | Phase 3 | Enrolling by invitation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2023-02-15 | 2025-02-10 |
| Allogeneic Transplant in HIV Patients (BMT CTN 0903) Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine - Leukemia, Lymphoma | Phase 2 | Completed | Medical College of Wisconsin | 20 | 2011-09-01 | 2022-12-08 |
| Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine - Leukemia, Myelocytic, Acute | Phase 3 | Terminated | Medical College of Wisconsin | 272 | 2011-06-01 | 2023-01-04 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Leukemia (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Medical College of Wisconsin (2) · First Affiliated Hospital of Zhejiang University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (2) · United States (2)
Mary Horowitz, MD (2) · Linghui Xia, Professor (1)
U01HL069294 (2), U24CA076518 (2)